Who
Patrick D. Walsh
Director
Company insider
Files Form 4 as: Chairman, Interim Pres. & CEO, ANI Pharmaceuticals; Director, Lifecore Biomedical; Director, Avid Bioservices.
In numbers
- Trades disclosed
- 35
- Buys
- 6
- Sells
- 5
- Bought
- $917K
- Sold
- $4.7M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 20 Oct 2017
- Last trade
- 13 May 2026
- Last filed
- 13 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 13 May 2026filed 13 May 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $806K10,000 at $80.63 | filing |
| 13 May 2026filed 13 May 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $806K10,000 at $80.63 | filing |
| 11 May 2026filed 13 May 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $321K3,973 at $80.75 | filing |
| 11 May 2026filed 13 May 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $321K3,973 at $80.75 | filing |
| 3 Mar 2026filed 3 Mar 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $445K6,000 at $74.23 | filing |
| 3 Mar 2026filed 3 Mar 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $445K6,000 at $74.23 | filing |
| 13 Nov 2025filed 17 Nov 2025 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $751K8,643 at $86.88 | filing |
| 13 Nov 2025filed 17 Nov 2025 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code G | —3,000 at $0.00 | filing |
| 15 Aug 2025filed 18 Aug 2025 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $801K9,000 at $89.05 | filing |
| 22 May 2025filed 27 May 2025 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —4,336 at $0.00 | filing |
| 21 May 2024filed 23 May 2024 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —4,410 at $0.00 | filing |
| 23 May 2023filed 24 May 2023 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —6,865 at $0.00 | filing |
| 27 Apr 2022filed 29 Apr 2022 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —10,049 at $0.00 | filing |
| 21 Mar 2022filed 22 Mar 2022 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Bought | $139K5,000 at $27.76 | filing |
| 4 Jun 2021filed 8 Jun 2021 | LFCR Lifecore Biomedicaloption or derivative · Biotechnology | SEC FORM 4 Code A | —7,059 | filing |
| 20 Apr 2021filed 22 Apr 2021 | LFCR Lifecore BiomedicalBiotechnology | SEC FORM 4 Bought | $113K10,000 at $11.26 | filing |
| 23 Mar 2021filed 25 Mar 2021 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —9,292 at $0.00 | filing |
| 15 Mar 2021filed 17 Mar 2021 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Bought | $132K4,000 at $32.89 | filing |
| 14 Dec 2020filed 16 Dec 2020 | Avid Bioservicesoption or derivative | SEC FORM 4 Code A | —10,030 at $0.00 | filing |
| 14 Dec 2020filed 16 Dec 2020 | Avid Bioservicesoption or derivative | SEC FORM 4 Code A | —2,379 at $0.00 | filing |
News
ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ETANIP · manilatimes.net · 23 Oct 2026
0 headlines in the last 90 days name Patrick D. Walsh; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.